Blood
Gilead stops late-stage trial of blood cancer treatment
21
Jul
Jul
July 21 (Reuters) – Gilead Sciences Inc (GILD.O) said on Friday it was stopping a late-stage trial of its blood cancer treatment following an analysis.
Reporting by Sriparna Roy in Bengaluru
Editing by Vinay Dwivedi
Editing by Vinay Dwivedi
Our Standards: The Thomson Reuters Trust Principles.
